Cargando…
A retrospective classification of diagnoses in terms of DSM-5 for patients included in randomized controlled trials of Ginkgo biloba extract EGb 761(®)
When the early trials of Ginkgo biloba extract EGb 761(®) were conducted, different terms were used to denote ageing-associated neurocognitive disorders. With the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a taxonomy covering dementia and pre-dementia stages...
Autores principales: | Hoerr, Robert, Zaudig, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819753/ https://www.ncbi.nlm.nih.gov/pubmed/26267422 http://dx.doi.org/10.1007/s00406-015-0632-y |
Ejemplares similares
-
Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review
por: Hort, Jakub, et al.
Publicado: (2023) -
The Effect of Ginkgo Biloba (EGb 761) on Epileptic Activity in Rabbits
por: Ivetic, Vesna, et al.
Publicado: (2008) -
Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761(®). Findings from a randomized controlled trial
por: Bachinskaya, Natalia, et al.
Publicado: (2011) -
Treatment of Vertigo: A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine
por: Sokolova, Larysa, et al.
Publicado: (2014) -
The Ginkgo biloba Extract EGb 761 Modulates Proteasome Activity and Polyglutamine Protein Aggregation
por: Stark, Marcel, et al.
Publicado: (2014)